Methods for the in vitro determination of the outcome and for the treatment of individuals having multiple myeloma

A method for treating an individual having a multiple myeloma, able to respond to a therapeutic anti-multiple myeloma (anti-MM) treatment, comprising the steps of:

• a) identifying the individual able to respond to the therapeutic anti-MM treatment by performing the following steps:
• i) measuring the expression level of at least 2 genes encoding a ROS detoxifying (AOX) protein selected in a group comprising AKR1B1, ARNT, CAT, CBR1, DHCR24, EGLN1, GLRX2, HIF1A, MGST1, MSRB1, PRDX6, SLC7A11, SOD1, SRXN1, TALDO1 and TXN and/or the expression level of at least 2 genes encoding ROS producing (ROS) protein selected in a group comprising CYBA, CYB5A, CYC1, NCF1B, NCF1C, NCF4, NDUFA12, NDUFS2, NDUFS8, SHC1 and UQCR10, in a biological sample obtained from said individual;
• ii) calculating an AOX score value and/or a ROS score value from the said respective expression level obtained at step a);
• iii) comparing said AOX score value and/or said ROS score value to a respective predetermined reference value,
• iv) confirming that said AOX score value and/or said ROS score value is lower than the respective predetermined reference value and concluding that said individual is able to respond to said therapeutic anti-MM treatment,
• b) administering to said individual an effective amount of said therapeutic anti-MM treatment.